Intensification of upfront chemotherapy for patients with myeloid blast phase CML: a single center experience.

Ann Hematol · 2024 · PMC11695490 · PMID 39438320

Europe PMC DOI

hedged sentence

0.6400

closest p · 12.8× alpha

0.6400

boldest claim

The sentences

did not reach statistical significanceP = 0.64not close (p > 0.1)

Receipt of third-generation TKI, ponatinib, appeared to be associated with improved hematologic response yet did not reach statistical significance both in the full cohort (66.7% vs. 50%, P = 0.64) and for those with prior CP/AP (66.7% vs. 28.6%; P = 0.29).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.